Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12431600 | 0.82 | ALDH1A1 (0.71) | KDM4ESMN1; SMN2ALDH1A1HPGDPOLB | |
| SCHEMBL5805385 | 0.81 | ALDH1A1 (0.70) | KDM4ESMN1; SMN2ALDH1A1HPGDPOLB | |
| SCHEMBL14091323 | 0.79 | SMN1; SMN2 (0.67) | KDM4ESMN1; SMN2ALDH1A1HPGDPOLB | |
| SCHEMBL12431599 | 0.79 | SMN1; SMN2 (0.70) | KDM4ESMN1; SMN2ALDH1A1HPGDPOLB | |
| SCHEMBL5823576 | 0.79 | HPGD (0.65) | ALDH1A1HPGDPOLBMAPTLMNA | |
| SCHEMBL20765543 | 0.75 | SMN1; SMN2 (0.79) | KDM4ESMN1; SMN2ALDH1A1HPGDPOLB | |
| SCHEMBL5756447 | 0.75 | GRIA3 (0.66) | KDM4ESMN1; SMN2ALDH1A1HPGDPOLB | |
| SCHEMBL5823589 | 0.74 | CRBN (0.54) | KDM4ESMN1; SMN2ALDH1A1HPGDPOLB | |
| SCHEMBL20765504 | 0.74 | ALDH1A1 (0.64) | KDM4ESMN1; SMN2ALDH1A1HPGDPOLB | |
| SCHEMBL20765762 | 0.73 | L3MBTL1 (0.62) | KDM4ESMN1; SMN2ALDH1A1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | disclosed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, BDNF, NGF | KDM4E 4630/4885SMN1; SMN2 70/4885ALDH1A1 2314/4885 |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, NGF, BDNF | KDM4E 4841/4885SMN1; SMN2 57/4885ALDH1A1 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.